ArticleHarm reduction journal2026
A novel model of care; Telemedicine and peer support for HCV care among HIV-infected people who inject drugs in remote Myanmar: a retrospective study.
Article in Harm reduction journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople who inject drugs (PWID) are at increased risk of co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Uncontrolled HCV infection contributes to ongoing transmission among PWID, underscoring the urgent need to expand access to treatment as a public health priority. Despite the availability of highly effective direct-acting antiviral therapy, access remains limited, particularly in remote areas where stigma and structural barriers complicate care delivery. Implementing integrated and differentiated HCV care models in these settings may help address this gap. This study evaluated a novel care model in remote areas in which general practitioners delivered integrated HCV and HIV care, supported by specialist telemonitoring, community health workers, and peer educators. We assessed treatment outcomes and associated predictors.
methodsRoutine program data from the HCV treatment register were used to assess treatment completion and sustained viral response (SVR) among PWID. SVR12 was defined as an undetectable HCV viral load at 12 weeks after treatment completion. Patients who achieved SVR12 were invited for retesting at one year to calculate the one-year SVR rate (SVR64). Logistic regression analyses were performed to identify predictors of both SVR12 and SVR64.
resultsAmong 314 HIV-HCV co-infected PWID who initiated HCV treatment, 69.7% (219 of 314) achieved SVR12, and after one year, 57.5% (126 of 219) achieved SVR64, based on intention-to-treat analysis. Participants aged ≥ 25 years were significantly more likely to achieve both SVR12 and SVR64. Methadone maintenance therapy (aOR: 2.6; 95% CI: 1.5-4.4), not being an active PWID (aOR: 1.5; 95% CI: 1.0-2.5), and advanced liver disease: fibrosis (aOR: 2.3; 95% CI: 1.2-4.2) and cirrhosis (aOR: 2.9; 95% CI: 1.3-6.3), were independently associated with SVR64 (p ≤ 0.05).
conclusionA novel care model involving general practitioners, specialist telemonitoring, and support from community health workers and peer educators demonstrated effectiveness in achieving SVR among HIV-HCV co-infected PWID in remote settings. Further qualitative research is warranted to better understand the factors influencing HCV treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.